Literature DB >> 15248205

The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis.

Paco M J Welsing1, Robert B M Landewé, Piet L C M van Riel, Maarten Boers, Anke M van Gestel, Sjef van der Linden, Hilde L Swinkels, Désirée M F M van der Heijde.   

Abstract

OBJECTIVE: Radiologic progression in rheumatoid arthritis (RA) is considered the consequence of persistent inflammatory activity. To determine whether a change in disease activity is related to a change in radiologic progression in individual patients, we investigated the longitudinal relationship between inflammatory disease activity and subsequent radiologic progression.
METHODS: The databases of the University Medical Center Nijmegen (UMCN) cohort and the Maastricht Combination Therapy in RA (COBRA) followup study cohort were analyzed. The UMCN cohort included 185 patients with early RA who were followed up for up to 9 years. Patients were assessed every 3 months for disease activity and every 3 years for radiologic damage. The COBRA cohort included 152 patients with early RA who were followed up for up to 6 years. Patients were assessed at least every year for disease activity and every 12 months for radiologic damage. Disease activity was assessed with the Disease Activity Score (DAS) (original DAS in the UMCN cohort, DAS28 in the COBRA cohort). Radiologic damage was measured by the Sharp/van der Heijde score in both cohorts. Data were analyzed with longitudinal regression analysis (generalized estimating equations [GEE]), using autoregression for longitudinal associations and radiologic damage as the dependent variable. Time, time(2) baseline predictors for radiologic progression and their interactions with time, as well as DAS/DAS28 (actual values or interval means and interval SDs of the means) were subsequently modeled as explanatory variables.
RESULTS: Data analyzed by GEE showed a decrease in radiologic progression over time (regression coefficient for time(2) -1.0 [95% confidence interval -1.4, -0.6] in the UMCN cohort and -0.4 [95% confidence interval -0.8, 0.0] in the COBRA cohort). After adjustment for time effects and baseline predictors of radiologic progression and their interactions with time, a positive longitudinal relationship was indicated by autoregressive GEE between the mean interval DAS and radiologic progression in the UMCN cohort (regression coefficient 5.4 [95% confidence interval 2.1, 8.6]), and between the DAS28 and radiologic progression in the COBRA cohort (regression coefficient 1.4 [95% confidence interval 0.8, 2.0]). In the UMCN cohort, the SD of the mean interval DAS was independently longitudinally related to the radiologic progression over the same periods (regression coefficient 20.2 [95% confidence interval 7.2, 33.3]). In both cohorts, the longitudinal relationships between (fluctuations in) disease activity and radiologic progression were found selectively in rheumatoid factor (RF)-positive patients.
CONCLUSION: Radiologic progression is not linear in individual patients. Fluctuations in disease activity are directly related to changes in radiologic progression, which supports the hypothesis that disease activity causes radiologic damage. This relationship might only exist in RF-positive patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15248205     DOI: 10.1002/art.20350

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  73 in total

1.  Intra-individual assessment of inflammatory severity and cartilage composition of finger joints in rheumatoid arthritis.

Authors:  C Schleich; A Müller-Lutz; P Sewerin; B Ostendorf; C Buchbender; M Schneider; G Antoch; F Miese
Journal:  Skeletal Radiol       Date:  2014-11-01       Impact factor: 2.199

2.  Factors that influence rheumatologists' decisions to escalate care in rheumatoid arthritis: results from a choice-based conjoint analysis.

Authors:  Wietske Kievit; Laura van Hulst; Piet van Riel; Liana Fraenkel
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

3.  Rheumatoid arthritis: defining remission in patients with RA in clinical practice.

Authors:  Rene Westhovens; Patrick Verschueren
Journal:  Nat Rev Rheumatol       Date:  2012-07-03       Impact factor: 20.543

4.  Great expectations of modern RA treatment.

Authors:  S Irvine; H C Capell
Journal:  Ann Rheum Dis       Date:  2005-09       Impact factor: 19.103

5.  EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors:  B Combe; R Landewe; C Lukas; H D Bolosiu; F Breedveld; M Dougados; P Emery; G Ferraccioli; J M W Hazes; L Klareskog; K Machold; E Martin-Mola; H Nielsen; A Silman; J Smolen; H Yazici
Journal:  Ann Rheum Dis       Date:  2006-01-05       Impact factor: 19.103

Review 6.  Presentation and analysis of radiographic data in clinical trials and observational studies.

Authors:  R Landewé; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

7.  Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction?

Authors:  Georg Schett; Robert Landewé; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2007-06       Impact factor: 19.103

8.  Examining radiographic outcomes over time.

Authors:  Grace S Park; Weng Kee Wong; Dinesh Khanna; Richard H Gold; Harold E Paulus
Journal:  Rheumatol Int       Date:  2013-10-29       Impact factor: 2.631

9.  [Austrian expert opinion on the standard for expert assessment of course of illness in patients with chronic polyarthritis (rheumatoid arthritis)].

Authors:  Klaus P Machold; Hans Peter Brezinsek; Burkhard F Leeb; Stephan Pflugbeil; Franz Rainer; Franz Singer; Martin Skoumal; Tanja A Stamm; Manfred Herold
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 10.  Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop.

Authors:  Vivian P Bykerk; Elisabeth Lie; Susan J Bartlett; Rieke Alten; Annelies Boonen; Robin Christensen; Daniel E Furst; Sarah Hewlett; Amye L Leong; Anne Lyddiatt; Lyn March; James E May; Pam Montie; Ana-Maria Orbai; Christoph Pohl; Marieke Scholte Voshaar; Thasia Woodworth; Clifton O Bingham; Ernest H Choy
Journal:  J Rheumatol       Date:  2014-03-01       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.